Mixed Dyslipidemia: Clinical Trials

5 trials for Mixed Dyslipidemia, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 active not recruiting, 1 not yet recruiting, 1 recruiting. 5 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 25Completed 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1

Follow Mixed Dyslipidemia: new trials by email Literature Review of Mixed Dyslipidemia trials Research Report on Mixed Dyslipidemia

Trials (filtered) newest first · largest first

All 5 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia
EDP167 100mg, EDP167 200mg, EDP167 300mg - Mixed Dyslipidemia
Phase 2Not yet recruitingEddingpharm (Zhuhai) Co., Ltd.1442026-11-012026-09-02
Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia
MWX203, Inclisiran Sodium Injection, Placebo - Mixed Dyslipidemia
Phase 2RecruitingShanghai Minwei Biotechnology Co., Ltd2162026-09-252026-09-08
A Study in Patients With Mixed Dyslipidemia
BW-00112 - Mixed Dyslipidemia
Phase 2Active not recruitingShanghai Argo Biopharmaceutical Co., Ltd.1452024-02-282026-01-13
Study of Plozasiran (ARO-APOC3) in Adults With Mixed Dyslipidemia
ARO-APOC3, Placebo - Mixed Dyslipidemia
Phase 2CompletedArrowhead Pharmaceuticals3532021-09-282026-04-14
Study of ARO-ANG3 in Adults With Mixed Dyslipidemia
ARO-ANG3, Placebo - Mixed Dyslipidemia
Phase 2CompletedArrowhead Pharmaceuticals2042021-06-282025-12-03

Narrower conditions

Dyslipidemias (1)

Broader conditions

Lipid Metabolism Disorders (1)  ·  Metabolic Diseases (1)  ·  Nutritional and Metabolic Diseases (1)

Interventions

plozasiran (1)

Sponsors

Arrowhead Pharmaceuticals (2)  ·  Eddingpharm (Zhuhai) Co., Ltd. (1)  ·  Shanghai Argo Biopharmaceutical Co., Ltd. (1)  ·  Shanghai Minwei Biotechnology Co., Ltd (1)

Countries

United States (3)  ·  Australia (2)  ·  Canada (2)  ·  China (2)  ·  New Zealand (2)  ·  Hungary (1)  ·  Poland (1)

Top investigators

Yuqiong Li, Master (1)

Results publications

PMID 38682459, PMID 38804517, PMID 38809174, PMID 42496147